FINANCE

Three NYSE Stocks at 52-Week Lows That Look Worth a Closer Look

Bloomberg reports that the cyclically adjusted price-earnings multiple (CAPE) is above 40 for only the second time in the past 25 years.

Unsurprisingly, only 50 NYSE stocks hit new 52-week lows compared to 110 new 52-week highs. Over on the

Nasdaq, 347 hit new 52-week highs, over three times the number of new 52-week lows.

I believe stocks are expensive and a correction is likely in the next 12 months. Further, the U.S. economy is not nearly as strong as the White House would like us to believe.

An out-of-control stock market is not the same thing as an economy running on all cylinders. I hope we don’t learn the hard way, but we usually do.

Enough of the negative vibes. The Blue Jays continue to battle in the World Series. That’s good enough for me.

Looking at yesterday’s 50 new 52-week lows, I’ve found at least three stocks worth a closer look.

Church & Dwight (CHD) hit its 18th new 52-week low yesterday. Its stock is down over 16% over the past 12 months.

The maker of household, personal care, and specialty products is best known for its Arm & Hammer baking soda and related products, such as kitty litter and toothpaste. Other brands include Oxi Clean, Trojan, Orange Glo, L’il Critters, Gravol, and Waterpik.

I’ve followed CHD for years. At one point, its stock had produced over 10 consecutive years of annual gains. Since Oct. 1, 2005, its shares have appreciated by 862%. Add in dividends over this period, and you’re over 1,000%.

Of course, it’s down 16% in 2025 for a reason.

The most obvious is that organic sales growth has come to a screeching halt. In Q2 2025, they grew by a measly 0.1%, with a 1.4% decline in U.S. organic sales, which accounted for 77% of overall sales.

Secondly, its margins have fallen in recent quarters. In Q2 2025, its gross margin was 43.0%, 410 basis points lower than a year ago, while its operating margin was 17.5%, 480 points lower.

Lastly, it expects net sales in 2025 to increase by just 1% at the midpoint of its guidance, with adjusted earnings per share to increase by the same amount.

So, why buy if pain remains in clear view?

While it’s not trading anywhere near a 25-year low enterprise value-to-revenue multiple — that was in December 2000 at 1.04x, according to S&P Global Market Intelligence — its 4.21x multiple is the lowest since 2018.


Source link

Related Articles

Back to top button